RRM1

Ribonucleoside-diphosphate reductase large subunit • UniProt accession P23921

Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides

Source: UniProt

Heterodimer of a large and a small subunit. Heterodimer with small subunit RRM2 or RRM2B. The heterodimer with RRM2 has higher catalytic activity than the heterodimer with RRM2B.

Interacts with AHCYL1 which inhibits its activity

Source: UniProt
Cytoplasm
Source: UniProt
  • Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 6 (PEOB6)

    A form of progressive external ophthalmoplegia, a mitochondrial myopathy characterized by progressive paralysis of the levator palpebrae, orbicularis oculi, and extraocular muscles. Ragged red fibers are seen on muscle biopsy.

Source: UniProt
  • Interconversion of nucleotide di- and triphosphates
Source: Reactome via UniProt

Mutations

No mutation information available.

Synthetic Lethal Network

Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to RRM1, aggregated across our SSL data sources. Click any partner node to view that gene’s page.

Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.

BioGRID SLOrth SynLethDB MexDrugs Multi-source
Sources: BioGRID, SLOrth, SynLethDB, MexDrugs

Clinical Trials

Total Trials Found: 2420

NCT ID Condition Brief Title Phase Status
NCT01648517 Non-small Cell Lung Carcinoma Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy PHASE2 COMPLETED
NCT00792701 Lung Cancer S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer PHASE2 COMPLETED
NCT00499109 Non-Small Cell Lung Cancer Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC PHASE3 COMPLETED
NCT01424709 Non-small Cell Lung Cancer Individualized Chemotherapy Based on BRCA1 and RRM1 mRNA for Advanced Non-small Cell Lung Cancer (NSCLC) PHASE2 UNKNOWN
NCT01781988 Lung Cancer, Carboplatin Adverse Reaction Personalized Therapy in Non-small Cell Lung Cancer PHASE2 COMPLETED
NCT00736814 Lung Cancer First-Line Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery PHASE2 UNKNOWN
NCT00705549 Non-Small-Cell Lung Cancer Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer PHASE2 TERMINATED